I no longer remember actual facts from the Phase 2 trial 2012, but with the control and 1 mg Bavi arms being combined for presentation to the FDA for Phase 3 consideration, is it logical to assume that said control arm as combined also performed better than historical values of docetaxel[e.g. Herbst]? Did it? How much better, if any, did the 3mg Bavi containing arm perform than that combined control arm?
Market Data 
Markets 
AI
